Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IBRXthis companyImmunityBio, Inc.	$7.00	-5.21×	-3.65×	16.08×	-11.68×	-355.9%	99.3%	-226.0%	-310.2%	70.3%	-56.9%	-17.0%	-1.76×	-3.53×	-2.28×	5.1×	0.0%	3	-10.89	2	C
ALLOAllogene Therapeutics, Inc.	$1.05	-1.57×	1.03×	0×	-1.88×	-114.2%	0.0%	0.0%	0.0%	-65.3%	-52.8%	-49.5%	0.28×	-0.18×	-192.5×	7.93×	0.0%	4	-3.65	2	C
ATRAAtara Biotherapeutics, Inc.	$8.18	6.93×	-5.89×	1.88×	7.02×	-5049.6%	82.4%	29.7%	27.1%	-84.9%	222.7%	-22.4%	-1.37×	1.15×	9.46×	0.82×	0.0%	1	-135.86	2	C
IOVAIovance Biotherapeutics, Inc.	$8.54	-2.5×	1.4×	3.7×	-2.45×	-50.5%	34.3%	-151.1%	-148.4%	-56.0%	-50.9%	-34.5%	0.07×	0.33×	0×	3.2×	0.0%	4	7.46	2	C
LEGNLegend Biotech Corporation	$24.18	-13.59×	4×	3.89×	-15.15×	-9886.0%	60.3%	-13.3%	-28.8%	-29.6%	-9.6%	-4.2%	0.41×	2.1×	-6.38×	1.96×	0.0%	3	4.12	1	C-
MRNAModerna, Inc.	$271.95	-4.06×	1.33×	5.9×	-4.23×	-100.7%	55.3%	-158.1%	-145.2%	-32.6%	-29.7%	-18.0%	0.22×	0.27×	-307.4×	3.29×	0.0%	2	12.95	1	C-
Peer median	—	-2.5×	1.33×	3.7×	-2.45×	-114.2%	55.3%	-13.3%	-28.8%	-56.0%	-29.7%	-22.4%	0.22×	0.33×	-6.38×	3.2×	0.0%	3	4.12	2	—